ORAMED PHARMACEUTICALS INC. (ORMP) is a publicly traded company in the Unknown sector. Across all available filings, 23 corporate insiders have executed 197 transactions totaling $17.1M, demonstrating a bearish sentiment with -$10.0M in net insider flow. The most recent transaction on Jun 21, 2024 involved a transaction of 140,040 shares valued at $0.
No significant insider buying has been recorded for ORMP in the recent period.
No significant insider selling has been recorded for ORMP in the recent period.
Based on recent SEC filings, insider sentiment for ORMP is bearish with an Insider Alignment Score of 21/100 and a net flow of -$10.0M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ORAMED PHARMACEUTICALS INC. (ORMP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 23 insiders are actively trading ORMP stock, having executed 197 transactions in the past 90 days. The most active insider is Nadav Kidron (Executive), who has made 39 transactions totaling $11.0M.
Get notified when executives and directors at ORMP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 21, 2024 | Gabay Avraham | Executive | Award | 140,040 | $N/A | $0 | |
| Jun 6, 2024 | Reznick Yehuda | Executive | Award | 760 | $N/A | $0 | |
| Apr 17, 2024 | Reznick Yehuda | Executive | Award | 29,800 | $N/A | $0 | |
| Jan 30, 2024 | Aghion Daniel | Executive | Award | 3,750 | $N/A | $0 | |
| Jan 4, 2024 | Shapiro Benjamin | Executive | Award | 30,000 | $N/A | $0 | |
| Jan 4, 2024 | Shapiro Benjamin | Executive | Award | 5,070 | $N/A | $0 | |
| Jan 4, 2024 | Aghion Daniel | Executive | Award | 5,070 | $N/A | $0 | |
| Jan 4, 2024 | Aghion Daniel | Executive | Award | 30,000 | $N/A | $0 | |
| Jan 4, 2024 | Mayer Arie | Executive | Award | 30,000 | $N/A | $0 | |
| Jan 4, 2024 | Mayer Arie | Executive | Award | 9,325 | $N/A | $0 | |
| Jan 4, 2024 | Rozov Yadin | Executive | Award | 30,000 | $N/A | $0 | |
| Jan 4, 2024 | Rozov Yadin | Executive | Award | 8,820 | $N/A | $0 | |
| Jan 4, 2024 | Sank Leonard | Executive | Award | 9,325 | $N/A | $0 | |
| Jan 4, 2024 | Sank Leonard | Executive | Award | 30,000 | $N/A | $0 | |
| Jan 4, 2024 | Silberman David | Executive | Award | 136,500 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 24 | $13.6M | 55.4% |
Purchase(P) | 46 | $3.6M | 14.6% |
Payment(F) | 11 | $2.7M | 10.9% |
Other(J) | 2 | $1.7M | 6.8% |
Exercise(M) | 15 | $1.3M | 5.5% |
Exercise (Options)(X) | 1 | $1.1M | 4.5% |
Award(A) | 87 | $594.7K | 2.4% |
Small Acquisition(L) | 2 | $3.5K | 0.0% |
Gift(G) | 9 | $0 | 0.0% |
Insider selling pressure at ORAMED PHARMACEUTICALS INC. has increased, with 23 insiders executing 197 transactions across all time. Total sales of $13.6M significantly outpace purchases of $3.6M, resulting in a net outflow of $10.0M. This selling activity appears largely discretionary, which may warrant closer attention from investors.